Navigation Links
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Date:11/11/2008

("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH").

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to obtain Asian partners to further develop Convivia(TM); Raptor's ability to manufacture clinical scale quantities of its proprietary Convivia(TM) formulation; Convivia's(TM) ability to benefit ALDH2 deficient individuals by lessening their exposure to acetaldehyde and mitigating their unpleasant reactions to drinking; the ability of Convivia(TM) to be successfully developed into a marketable treatment; and Raptor's ability to successfully develop any of its other clinical and preclinical products. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which m
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
2. Raptor Pharmaceuticals Provides Update on Targeting Platforms
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
8. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
11. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ...   Operating results for the first quarter of ... and other achievements, include: , Worldwide net product sales ... international net sales of $13.2 million, an increase of 14.5% ... sales reached a new high of $58.8 million, an increase ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/21/2014)... DMG Productions announces the upcoming airing of Innovations ... August 25, 2014 at 7:00 a.m. EST and 7:00 ... episode, Innovations will go behind-the-scenes to demonstrate how Freenotes ... Audiences will be amazed by the park's that focus ... providing access to real musical instruments. , Audiences will ...
(Date:8/21/2014)... August 21, 2014 Being overweight or ... painful osteoarthritis. Although there is no cure, patients have ... making certain lifestyle changes, such as losing excess weight ... , Osteoarthritis is a joint disorder which causes discomfort ... and neck and can significantly reduce one’s quality of ...
(Date:8/21/2014)... Australian scientists say a commercially available compound ... used to successfully fight mesothelioma in lab mice. Surviving ... research. Click here to read it now. ... mesothelioma cells with the S. aureus mixture ... simultaneously stimulating a stronger anti-tumor response in healthy cells. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... wellness in all aspects of life, St. Louis’ Sound ... for the better and revolutionized its online presence. Reorganized ... Mind Café, the new website makes navigating for information ... blue and an easily accessible menu-bar in jet black, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Bunion Bootie ... Pedorthics, a bi-monthly publication of the Pedorthic Footcare Association and ... , Bunion Bootie is a new ... for bunion sufferers and their pain. It is extremely comfortable ... any shoe to eliminate the friction and rubbing of shoes ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 3Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3
... China is implementing family planning policies is often held ... ,Well the element of coercion may be ... exploding beyond relentlessly.,The riots against punitive measures reported last ... being done over there.,Worse, the Chinese citizens are virtually ...
... stents in the treatment of coronary artery blockage is common ... patients receiving drug-coated stents for off-label indications, according to ... ,Stents are tiny mesh tubes used to prop open ... obstructed coronary artery. The newer drug-eluting stents are normal metal ...
... of tuberculosis in Britain, senior doctors here want all ... the disease. ,The doctors want the ... ,The Observer reported Sunday that two new outbreaks, in ... officials were failing to come to grips with the ...
... Researchers studying the genetics behind why C. difficile causes disease ... it because they are starving. That just might help them ... a very difficult disease to treat. ,"The genes ... periods of nutrient deprivation. This is consistent with the view ...
... person dies of it every 30 seconds, it rivals HIV ... vast majority of its victims are under five years old. ... Ross was awarded the Nobel Prize for finally proving that ... Nottingham believe they have made a significant breakthrough in the ...
... Commissioner for Human Rights: 'Universal access to health care is not ... cannot implement that human right without effective health systems. We ... this simple message stick.' ,The International Day ... year. ,The origins of this world health day ...
Cached Medicine News:Health News:Chinese Take Fertility Drugs to Beat One Child Policy 2Health News:Chinese Take Fertility Drugs to Beat One Child Policy 3Health News:Off-label and Untested Use of Drug-coated Stents Appears Widespread 2Health News:Understanding Why C. Difficile Causes Disease -- It's Hungry 2Health News:Vaccine Hope for Malaria 2Health News:International Day Of Action For Women's Health - 2007 2Health News:International Day Of Action For Women's Health - 2007 3Health News:International Day Of Action For Women's Health - 2007 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: